Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

MeiraGTx Holdings Yönetim

Yönetim kriter kontrolleri 3/4

MeiraGTx Holdings' CEO'su Alexandria Forbes, Mar2015 tarihinde atandı, in görev süresi 9.58 yıldır. in toplam yıllık tazminatı $ 6.34M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.2% maaş ve 89.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.81% ine doğrudan sahiptir ve bu hisseler $ 5.84M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.4 yıl ve 9.3 yıldır.

Anahtar bilgiler

Alexandria Forbes

İcra Kurulu Başkanı

US$6.3m

Toplam tazminat

CEO maaş yüzdesi	10.2%
CEO görev süresi	9.6yrs
CEO sahipliği	1.8%
Yönetim ortalama görev süresi	5.4yrs
Yönetim Kurulu ortalama görev süresi	9.3yrs

Son yönetim güncellemeleri

Recent updates

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

Jul 15

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year

Mar 16

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be

Nov 16

MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

Aug 11

MeiraGTx inks $100M debt agreement backed by manufacturing facilities

Aug 03

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

Apr 29

Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher

Mar 15

MeiraGTx: Perceptive's Large Stake Makes It Interesting

Jan 19

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

Dec 28

CEO Tazminat Analizi

Alexandria Forbes'un ücretlendirmesi MeiraGTx Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$93m
Mar 31 2024	n/a	n/a	-US$74m
Dec 31 2023	US$6m	US$648k	-US$84m
Sep 30 2023	n/a	n/a	-US$132m
Jun 30 2023	n/a	n/a	-US$125m
Mar 31 2023	n/a	n/a	-US$129m
Dec 31 2022	US$8m	US$580k	-US$130m
Sep 30 2022	n/a	n/a	-US$112m
Jun 30 2022	n/a	n/a	-US$101m
Mar 31 2022	n/a	n/a	-US$87m
Dec 31 2021	US$6m	US$580k	-US$80m
Sep 30 2021	n/a	n/a	-US$80m
Jun 30 2021	n/a	n/a	-US$61m
Mar 31 2021	n/a	n/a	-US$66m
Dec 31 2020	US$8m	US$602k	-US$58m
Sep 30 2020	n/a	n/a	-US$53m
Jun 30 2020	n/a	n/a	-US$57m
Mar 31 2020	n/a	n/a	-US$52m
Dec 31 2019	US$8m	US$580k	-US$55m
Sep 30 2019	n/a	n/a	-US$70m
Jun 30 2019	n/a	n/a	-US$75m
Mar 31 2019	n/a	n/a	-US$86m
Dec 31 2018	US$23m	US$555k	-US$85m
Sep 30 2018	n/a	n/a	-US$73m
Jun 30 2018	n/a	n/a	-US$66m
Mar 31 2018	n/a	n/a	-US$42m
Dec 31 2017	US$1m	US$450k	-US$32m

Tazminat ve Piyasa: Alexandria 'nin toplam tazminatı ($USD 6.34M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.40M ).

Tazminat ve Kazançlar: Alexandria 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Alexandria Forbes (59 yo)

9.6yrs

Görev süresi

US$6,336,832

Tazminat

Dr. Alexandria Forbes, Ph.D. serves as the Chief Executive Officer, Director and President at MeiraGTx Holdings plc (formerly known as MeiraGTx Limited) since March 2015. Prior to joining MeiraGTx, Dr. For...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alexandria Forbes	CEO, President & Director	9.6yrs	US$6.34m	1.81% $ 5.9m
Richard Giroux	COO & CFO	9.6yrs	US$4.98m	1.2% $ 3.9m
Stuart Naylor	Chief Development Officer	9.5yrs	US$2.50m	0.73% $ 2.4m
Robert Wollin	General Counsel & Secretary	5.2yrs	Veri yok	0.020% $ 64.0k
Michel Michaelides	Head of Clinical Ophthalmology	3.8yrs	Veri yok	Veri yok
Christine Sheehy	Senior Vice President of Global Integration	no data	Veri yok	Veri yok
Tim Randall	Senior Vice President of Risk & Internal Controls	5.5yrs	Veri yok	Veri yok
Alastair Leighton	Senior Vice President of Manufacturing & Supply Chain	5.3yrs	Veri yok	Veri yok
Robert Zeldin	Chief Medical Officer	4.2yrs	US$4.05m	0.12% $ 379.5k

5.4yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: MGTX 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alexandria Forbes	CEO, President & Director	9.6yrs	US$6.34m	1.81% $ 5.9m
Arnold Levine	Member of Scientific Advisory Board	no data	US$149.82k	0% $ 0
Thomas Shenk	Independent Director & Member of Scientific Advisory Board	9.3yrs	US$347.73k	0% $ 0
Keith Harris	Independent Chairman of the Board	9.3yrs	US$538.84k	0.065% $ 211.5k
Nicole Seligman	Independent Director	5.4yrs	US$395.76k	0.0065% $ 21.1k
Gregory Petsko	Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Kaplitt	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Neil Mendoza	Independent Director	9.3yrs	US$352.73k	0.017% $ 54.5k
Ellen Hukkelhoven	Director	7yrs	US$264.23k	0% $ 0
James Alwine	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stefano Rivella	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Batey	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

9.3yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MGTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.3 yıldır).

MeiraGTx Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

MeiraGTx Holdings plc, Annual General Meeting, Jun 06, 2024

MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board

CEO, President & Director exercised options and sold US$101k worth of stock

CEO, President & Director exercised options and sold US$587k worth of stock

CEO, President & Director exercised options and sold US$222k worth of stock

CEO, President & Director exercised options and sold US$170k worth of stock

Recent updates

Consensus revenue estimates fall by 35%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

MeiraGTx Holdings plc has completed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 40% to US$21.20

Price target decreased by 19% to US$17.50

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

MeiraGTx Holdings (NASDAQ:MGTX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 11%, EPS upgraded

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)

MeiraGTx Holdings plc, Annual General Meeting, Jun 06, 2024

MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board

Price target decreased by 10.0% to US$21.60

New major risk - Financial position

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

CEO, President & Director exercised options and sold US$101k worth of stock

CEO, President & Director exercised options and sold US$587k worth of stock

Forecast to breakeven in 2025

MeiraGTx Holdings plc has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MeiraGTx Holdings plc announced that it has received $30 million in funding from Sanofi Foreign Participations B.V.

New minor risk - Share price stability

MeiraGTx Holdings plc Announces an Oral Presentation and Eight Posters At the European Society of Gene and Cell Therapy 2023 Annual Congress

Does MeiraGTx Holdings (NASDAQ:MGTX) Have A Healthy Balance Sheet?

Consensus revenue estimates decrease by 12%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MeiraGTx Holdings plc Announces Positive Clinical Data from the AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Holdings plc to Present 12-Month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MeiraGTx Holdings plc announced that it expects to receive $61.525 million in funding from Perceptive Advisors LLC, 683 Capital Management, LLC, Prosight Management, LP, Adage Capital Management, L.P.

Calculating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.4% to US$31.00

CEO, President & Director exercised options and sold US$222k worth of stock

CEO, President & Director exercised options and sold US$170k worth of stock

MeiraGTx Holdings plc cAnnounces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Consensus revenue estimates fall by 26%

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

MeiraGTx Holdings plc announced that it has received $24.999994 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx inks $100M debt agreement backed by manufacturing facilities

MeiraGTx Holdings plc Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients Treated with Botaretigene Sparoparvovec (AAV-RPGR) Compared to Untreated Randomized Control

Consensus forecasts updated

Price target decreased to US$30.57

MeiraGTx Holdings plc Presents Clinical Data on Botaretigene Sparoparvovec for Treatment of X-Linked Retinitis Pigmentosa at Association for Research in Vision and Ophthalmology 2022 Annual Meeting

MeiraGTx Holdings plc, Annual General Meeting, Jun 07, 2022

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

MeiraGTx Appoints Debra Yu to Board of Directors

Insufficient new directors

Insufficient new directors

Consensus revenue estimates increase by 28%

Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

MeiraGTx: Perceptive's Large Stake Makes It Interesting

CEO, President & Director exercised options and sold US$1.1m worth of stock

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Third quarter 2021 earnings released: US$0.59 loss per share (vs US$0.17 loss in 3Q 2020)

CEO Tazminat Analizi

CEO

Görev süresi